ATP6V0B: A Potential Drug Target and Biomarker (G533)

Target Name: ATP6V0B

NCBI ID: G533

ATP6V0B

Other Name(s): V-ATPase 21 kDa proteolipid subunit c'' | V-type proton ATPase 21 kDa proteolipid subunit c'' (isoform 1) | V-ATPase 21 kDa proteolipid subunit | ATPase, H+ transporting, lysosomal, 21-KD, V0 subunit

ATP6V0B: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the process of cell signaling. It is a small molecule that plays a vital role in the transfer of energy within cells. ATP is synthesized from the amino acids adenine, guanine, and phosphate. It is primarily synthesized in the liver, kidneys, and heart, and is broken down by the liver and kidneys to release its energy.

ATP has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key features of ATP is its high affinity for protein kinases, which are enzymes that regulate various cellular processes. These enzymes are known to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its role as a drug target, ATP has also been identified as a potential biomarker for several diseases. The high affinity of ATP for protein kinases makes it an attractive target for small molecule inhibitors. These inhibitors can be used to treat diseases where the over- activity of these enzymes is believed to contribute to the development and progression of the disease.

One of the key challenges in the development of ATP-based inhibitors is the design of the inhibitors. To be effective, these inhibitors must be able to selectively bind to ATP and inhibit the activity of protein kinases without interfering with other cellular processes. This has proven to be a challenging task, as many existing inhibitors have been shown to have unintended side effects.

Despite these challenges, recent studies have made significant progress in the development of ATP-based inhibitors. These inhibitors have been shown to be effective in preclinical studies in treating a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In the field of cancer, ATP-based inhibitors have been shown to be particularly effective in the treatment of breast cancer. Studies have shown that these inhibitors can significantly reduce the growth of cancer cells and inhibit their ability to spread. In addition, these inhibitors have been shown to have a low toxicity and can be easily administered to cancer patients.

In neurodegenerative diseases, such as Alzheimer's disease, ATP-based inhibitors have been shown to be effective in reducing the production of beta-amyloid plaques, a hallmark of the disease. These inhibitors have also been shown to improve the levels of a protein called tau, which is oftenabnormally produced in neurodegenerative diseases.

In cardiovascular diseases, ATP-based inhibitors have been shown to be effective in reducing the risk of heart failure and stroke in animal models of the disease. These inhibitors have also been shown to improve the levels of a protein called growth factors, which are often abnormally produced in cardiovascular diseases.

In conclusion, ATP is a molecule that has the potential to be a drug target and biomarker for a variety of diseases. Its high affinity for protein kinases and its role as a crucial molecule in the process of cell signaling make it an attractive target for small molecule inhibitors. The development of ATP-based inhibitors has the potential to revolutionize the treatment of a variety of diseases.

Protein Name: ATPase H+ Transporting V0 Subunit B

Functions: Proton-conducting pore forming subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:33065002). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity)

The "ATP6V0B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V0B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets